Ibvilda M 500 Tablet

The synergistic action of these two agents helps achieve better glycemic control by targeting multiple pathophysiological defects in type 2 diabetes. Ibvilda M 500 is typically prescribed as an adjunct to diet and exercise when monotherapy with either agent is insufficient to achieve adequate glycemic control. It is important to monitor renal function prior to and during treatment, as Metformin is contraindicated in patients with significant renal impairment.

Common adverse effects may include gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort, which often subside with continued use. Patients should be advised regarding the risk of hypoglycemia, particularly when used in combination with other antidiabetic agents. Regular monitoring of blood glucose levels and adherence to lifestyle modifications are essential for optimal therapeutic outcomes.